Loading stock data…
OLMA
$14.32-0.09 (-0.62%)
Market ClosedLast close May 1
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Olema Pharmaceuticals, Inc. in the Healthcare sector is trading at $14.32. The stock is currently 61% below its 52-week high of $36.26, remaining 9.8% below its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why OLMA maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.32
Potential Upside
5%
Whystock Fair Value$15.04
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$43.00+200.3%
Range$27.00 – $62.00
Fundamentals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.35B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.95%
Volume
Today's trading volume
712,592
Recent News
Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me”
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is one of the stocks highlighted in Jim Cramer’s latest Mad Money recap as he provided top stock insights. Answering a caller’s query about the stock, Cramer said: Too risky for me. I just think that at this stage, with this market, that one you could lose too much money. I’m […]
Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility
Olema Pharmaceuticals (NasdaqGS:OLMA) has filed a significant shelf registration that would allow it to issue additional securities. The filing creates a framework for potential future capital raising or funding transactions. The move represents a material corporate step that could influence Olema's financial flexibility and deal making options. Olema focuses on oncology drug development, so access to capital is a core part of how it funds clinical programs and related research. The new...
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.
Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Olema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.